Tim Garnett

Tim Garnett M.D, has served as an independent Director at Carmot Therapeutics since 2022. Prior to serving on the Carmot Board, Dr Garnett spent over 20 years at Eli Lilly in roles of increasing responsibility including serving as Chief Medical Officer from 2008 until 2021. At Lilly he led successful development of therapeutics in women’s health care, endocrinology and neuroscience through regulatory approval and successful launch in multiple geographies including the US, Europe, China and Japan. Dr Garnett has extensive experience leading clinical development, portfolio management, medical, regulatory and safety functions as well as a strategic understanding of the landscape for metabolic therapeutics.

Dr Garnett is a Board Member of Ophirex and a member of the Advisory Panel of Cambridge Innovation Capital. He holds a Bachelor of Medicine, Bachelor of Surgery (MBBS), is a Fellow of the Faculty of Pharmaceutical Medicine (FFPM), and a Fellow of the Royal College of Obstetricians and Gynaecologists (FRCOG).